Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Vedolizumab has proven efficacy in inflammatory bowel disease [IBD], but long-term mucosal healing in Crohn's disease [CD], as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been studied. We aimed to document mucosal healing and to explore the risk of colorectal neoplasia with vedolizumab maintenance therapy.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Crohns Colitis

Title: Journal of Crohn's & colitis

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1876-4479

ISSN (Print): 1873-9946

Publication date (Electronic): Sep 01 2017

Volume: 11

Issue: 9

Affiliations

[1 ] Division of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium.

[2 ] TARGID, KULeuven, Leuven, Belgium.

[3 ] Division of Pathology, University Hospital Leuven, Leuven, Belgium.

Article

Publisher Item ID: 3089704

DOI: 10.1093/ecco-jcc/jjx048

PubMed ID: 28369329

SO-VID: 34d299d2-8b02-47bd-aa28-5841f9beb0b8

History

Keywords: IBD,dysplasia,vedolizumab,healing

Data availability:

Keywords: IBD, dysplasia, vedolizumab, healing

Comments

Comment on this article

scite_

Cited by 26

See all cited by